Racura Oncology (ASX:RAC) Shareholder Yield % : -2.19% (As of Dec. 2025)


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.21
View Full Analysis

What is Racura Oncology Shareholder Yield %?

Racura Oncology ASX:RAC -5.96% 31 Shareholder Yield % is -2.19% as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 31/100. Among 1,300 Biotechnology companies, Racura Oncology ranks worse than 51.77% on this metric.

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. It is a measure of shareholder return. As of today, Racura Oncology's Shareholder Yield % was -2.19%.


Racura Oncology  (ASX:RAC) Shareholder Yield % Explanation

Shareholder Yield % is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. The term was coined by William W. Priest of Epoch Investment Partners in a paper in 2005 entitled The Case for Shareholder Yield as a Dominant Driver of Future Equity Returns. William Priest indicated that "shareholder yield is a term that we came up with to reflect the various ways dividends can be paid to owners of a business in a publicly-traded company."

Shareholder Yield % is calculated by three components: Dividend Yield %, Buyback Yield %, and Net Debt Paydown Yield %.

Dividend Yield % shows how much a company pays out in dividends each year relative to its stock price, which is most obvious form of shareholder return.

Buyback Yield % is the net repurchase of shares outstanding over the market capital of the company. Shares repurchases also increase shareholder value by returning the money back to shareholders.

Net Debt Paydown Yield % is the change in average of four quarters of company's total debt over a company's market cap. Assuming the total value of a company remains that same, shareholder value is increased as debt is reduced.


Racura Oncology Shareholder Yield % Related Terms


Racura Oncology Shareholder Yield % Historical Data

* Premium members only.

The historical data trend for Racura Oncology's Shareholder Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Shareholder Yield % Chart

Racura Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Shareholder Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.33 -9.81 0.64 -1.68 -0.52

Racura Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Shareholder Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.23 -1.68 -2.52 -0.52 -1.93

ASX:RAC vs VRTX, REGN, ALNY: Shareholder Yield % Comparison

For the Biotechnology subindustry, Racura Oncology's Shareholder Yield %, along with its competitors' market caps and Shareholder Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Racura Oncology Shareholder Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Racura Oncology's Shareholder Yield % distribution charts can be found below:

* The bar in red indicates where Racura Oncology's Shareholder Yield % falls into.


ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Shareholder Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Shareholder Yield % Calculation

Racura Oncology's Shareholder Yield % for the quarter that ended in Dec. 2025 is calculated as:

Shareholder Yield %=Dividend Yield %+Buyback Yield %+Net Debt Paydown Yield %
=0.00 %+-1.93 %+0 %
=-1.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* All the data are calculated by TTM values. Note that if a companies is traded in several exchanges, then we calculate the company level data for Shareholder Yield % using the primary share class stock data. The calculation result in definition page is for demonstration purpose only, and it's showing the share class level data. Therefore, the numbers in the calculation may differ from elsewhere if the stock is not a primary share.

Frequently Asked Questions Learn more about Shareholder Yield % →
What does a Shareholder Yield % of -2.19% mean?
Racura Oncology (ASX:RAC) has a Shareholder Yield % of -2.19% as of Dec. 2025. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Racura Oncology and its competitors. According to the industry distribution chart, Racura Oncology ranks #673 out of 1300 companies in the Biotechnology industry, placing it in the top 51.8%.
Is Racura Oncology's Shareholder Yield % too high?
Racura Oncology's current Shareholder Yield % is -2.19%. Based on the distribution chart, Racura Oncology ranks #673 out of 1300 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Shareholder Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Racura Oncology ranks #673 out of 1300 companies for Shareholder Yield %. This places Racura Oncology in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shareholder Yield % for a Biotechnology company?
A good Shareholder Yield % depends on the Biotechnology industry context. However, Shareholder Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shareholder Yield % mean?
A high Shareholder Yield % can signal that a stock is expensive relative to its fundamentals. Shareholder Yield is how much money shareholders receive from a company that is in the form of cash dividends, net stock repurchases, and debt reduction. View historical data on Racura Oncology and its competitors. Racura Oncology's current Shareholder Yield % is -2.19%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Shareholder Yield % of -2.19%. The current Shareholder Yield % is -2.19%. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shareholder Yield % calculated?
Shareholder Yield % is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Shareholder Yield % is -2.19% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Shareholder Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.21
Price